PharmSource-M&A in the CMC Services Industry: Implications and Outlook

PharmSource-M&A in the CMC Services Industry: Implications and Outlook


  • Products Id :- GDPS0017MAR
  • |
  • Pages: 36
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

PharmSource-M&A in the CMC Services Industry: Implications and Outlook

Summary

M&A is reshaping the bio/pharmaceutical contract development services industry. Established CMOs and CROs are pursuing acquisitions to drive scale and broaden their offerings, while private equity are anxious to either gain a presence in the industry or cash in on investments already made. Acquisitions of facilities divested by bio/pharma companies offer an alternative route for entering the industry or increasing capacity.

Scope

According to the latest PharmSource Trend Report, M&A in the CMC Services Industry: Implications and Outlook, in the three-year period 2014-2016 there were 101 acquisitions of CMC services companies, including dose and API manufacturing, packaging, logistics, formulation and analytical services. Only 25% of the targets had revenues greater than $100 million; most targets were small companies. Contrary to the popular impression, little industry consolidation has resulted from M&A.

M&A in the CMC Services Industry: Implications and Outlook analyzes how M&A in the bio/pharma contract services industry is likely to play out over the next two years. It examines which capabilities are likely to be most in demand by acquirers and which companies are most likely to be targets.

Reasons to buy

CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking

Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence

Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

Executive Summary

Objectives and Methodology

Overview of M&A Activity 2014-2016

Segment Close-Ups of M&A Activity 2014-1026

Valuations

Facility Acquisitions

What It Means

The Outlook for M&A in CMC Services

Appendix

1.2 List of Figures

Figure 1 Company Acquisitions 2014-2016 by Target Service Offering

Figure 2 Company Acquisitions 2014-2016 by Target Revenues

Figure 3 Company Acquisitions 2014-2016 by Target Ownership

Figure 4 Acquisition Targets by Sophistication of Capabilities

Figure 5 Number of Acquisitions by Buyer Rationale

Figure 6 Number of Acquisitions by Buyer's Core Business

Figure 7 Number of Acquisitions by Buyer Ownership

Figure 8 Number of Acquisitions by Principal Buyer Motivation

Figure 9 Dose Forms Manufactured by Acquired Dose Manufacturers

Figure 10 Bio/Pharma Facility Acquisitions 2014-2016

1.1 List of Tables

Table 1 CMC Services Businesses Acquired as Part of Larger Deals

Table 2 Company Acquisitions 2014-2016 by Target Service and Size

Table 3 Company Acquisitions 2014-2016 by Target Service and Ownership

Table 4 Company Acquisitions 2014-2016 by Target Market Scope and Size

Table 5 Most Active Acquirers 2014-2016

Table 6 Acquisitions of Dose Manufacturers

Table 7 Acquisitions of Biologics API Manufacturers

Table 8 Acquisitions of Small Molecule API Manufacturers

Table 9 Acquisitions of Analytical Services Providers

Table 10 Acquisitions of Formulation and CTM Providers

Table 11 Acquisitions of Packaging and Logistics Services Providers

Table 12 CMC Services Deals with Known Transaction Value and Multiples

Table 13 Facility Acquisitions by CMOs 2014-2016

Table 14 Number of Deals by Buyer and Target Service Offering

Table 15 Acquisitions by Private Equity Firms 2014-16

Table 16 Service Providers Owned 4+ Years by PE Firms

Table 17 Potential Targets: Biologics API Service Providers

Table 18 Potential Targets: Gene and Cell Therapy Providers

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license
Single User License
USD 2995 INR 212585
Site License
USD 5990 INR 425170
Corporate User License
USD 8985 INR 637755

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com